Mitoxantrone

Generic Name: Mitoxantrone

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₈N_₄O_₆

CAS Number: 65271-80-9

Unique Ingredient Identifier: BZ114NVM5P

Background: An anthracenedione-derived antineoplastic agent.

Indication: For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma

Associated Therapies: Autologous hematopoietic stem cell transplant

Clinical Trials

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

Phase 1

Terminated

Conditions: Acute Lymphoblastic Leukemia
Precursor B-Cell Lymphoblastic Leukemia
Precursor T-Cell Lymphoblastic Leukemia

Interventions: Drug: Decitabine
Drug: Vorinostat
Drug: Vincristine
Drug: Dexamethasone
Drug: Mitoxantrone
Drug: Pegaspargase
Drug: Methotrexate

First Posted Date: 2011-12-01

Last Posted Date: 2020-10-27

Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Target Recruit Count: 23

Registration Number: NCT01483690

Locations: 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇦🇺
Children's Hospital at Westmead, Westmead, New South Wales, Australia
🇦🇺
Sydney Children's Hospital, Sydney, Australia

and more 25 locations

A Study of Olaratumab (IMC-3G3) in Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Biological: Olaratumab
Drug: Prednisone
Drug: Mitoxantrone

First Posted Date: 2010-09-17

Last Posted Date: 2019-09-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 123

Registration Number: NCT01204710

Locations: 🇪🇸
ImClone Investigational Site, Valencia, Spain

Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)

Not Applicable

Completed

Conditions: AML

Interventions: Drug: Sirolimus
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2010-08-19

Last Posted Date: 2016-11-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 36

Registration Number: NCT01184898

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.

Phase 2

Terminated

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mitoxantrone
Drug: Rituximab

First Posted Date: 2010-06-15

Last Posted Date: 2016-10-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 8

Registration Number: NCT01144403

IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)

Phase 1

Terminated

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Plerixafor
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2009-12-09

Last Posted Date: 2015-01-26

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 6

Registration Number: NCT01027923

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Dasatinib
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Daunorubicin
Drug: Dexamethasone
Drug: Cytarabine
Drug: Mitoxantrone

First Posted Date: 2009-10-30

Last Posted Date: 2015-05-29

Lead Sponsor: The Catholic University of Korea

Target Recruit Count: 51

Registration Number: NCT01004497

Locations: 🇰🇷
Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Korea, Republic of
🇰🇷
Yonsei University Severance Hospital, Seoul, Korea, Republic of
🇰🇷
Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea, Republic of

and more 5 locations

Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: G-CSF
Drug: Plerixafor
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2009-05-21

Last Posted Date: 2017-04-04

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 39

Registration Number: NCT00906945

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Washington University, St. Louis, Missouri, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

Phase 2

Terminated

Conditions: Follicular Lymphoma

Interventions: Drug: Bendamustine
Drug: Mitoxantrone
Drug: Rituximab

First Posted Date: 2009-05-14

Last Posted Date: 2020-04-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT00901927

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias

Phase 1

Terminated

Conditions: Leukemia

Interventions: Drug: Clofarabine
Drug: Mitoxantrone
Drug: Etoposide

First Posted Date: 2009-04-16

Last Posted Date: 2019-07-24

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 22

Registration Number: NCT00882076

Locations: 🇺🇸
Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

Phase 4

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2009-02-27

Last Posted Date: 2020-04-07

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 100

Registration Number: NCT00853008

Locations: 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸
Clínica Teknon, Barcelona, Spain
🇪🇸
Hospital de Fuenlabrada, Madrid, Spain

and more 30 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy